Merck spin-off launches first slug of $9.5bn debt-raising
Organon, a spin-off of US pharmaceuticals company Merck, has launched the first $3bn of a $9.5bn capital raising that will give the soon-to-be independent group its own debt capital structure and fund a one-off special dividend to its parent.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: